Regulatory landscape for biosimilars in Latin America is uneven

04/10/2013 | PMLive.com (U.K.)

Economic growth in Latin America has increased the demand for and access to health care services, and government expenditures have risen accordingly, according to World Health Organization data. As complex biologic drugs account for an increasing proportion of spending, payers are looking to biosimilar drugs to contain costs. Despite the pressure, few countries have a clear pathway to biosimilars development and most are approaching the issue with caution.

View Full Article in:

PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL